Abstract

Neonates and children differ from adults in physiology, pharmacologic responses to drugs, epidemiology, and long-term consequences of thrombosis. This guideline addresses optimal strategies for the management of thrombosis in neonates and children. The methods of this guideline follow those described in the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. We suggest that where possible, pediatric hematologists with experience in thromboembolism manage pediatric patients with thromboembolism (Grade 2C). When this is not possible, we suggest a combination of a neonatologist/pediatrician and adult hematologist supported by consultation with an experienced pediatric hematologist (Grade 2C). We suggest that therapeutic unfractionated heparin in children is titrated to achieve a target anti-Xa range of 0.35 to 0.7 units/mL or an activated partial thromboplastin time range that correlates to this anti-Xa range or to a protamine titration range of 0.2 to 0.4 units/mL (Grade 2C). For neonates and children receiving either daily or bid therapeutic low-molecular-weight heparin, we suggest that the drug be monitored to a target range of 0.5 to 1.0 units/mL in a sample taken 4 to 6 h after subcutaneous injection or, alternatively, 0.5 to 0.8 units/mL in a sample taken 2 to 6 h after subcutaneous injection (Grade 2C). The evidence supporting most recommendations for antithrombotic therapy in neonates and children remains weak. Studies addressing appropriate drug target ranges and monitoring requirements are urgently required in addition to site- and clinical situation-specific thrombosis management strategies.

Keywords

MedicineAntithromboticHematologistGuidelinePartial thromboplastin timeDosingThrombosisIntensive care medicineHeparinPediatricsInternal medicineCoagulation

MeSH Terms

AnticoagulantsBlood Coagulation TestsCardiac CatheterizationChildChildPreschoolCooperative BehaviorDose-Response RelationshipDrugDrug Administration ScheduleEvidence-Based MedicineFactor Xa InhibitorsFibrinolytic AgentsHemorrhageHeparinHeparinLow-Molecular-WeightHumansInfantNewbornInterdisciplinary CommunicationPlatelet Aggregation InhibitorsRenal VeinsRisk FactorsSecondary PreventionSocietiesMedicalThrombosisUpper Extremity Deep Vein ThrombosisVitamin K

Affiliated Institutions

Related Publications

Publication Info

Year
2012
Type
article
Volume
141
Issue
2
Pages
e737S-e801S
Citations
1415
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1415
OpenAlex
73
Influential
1193
CrossRef

Cite This

Paul Monagle, Anthony K.C. Chan, Neil A. Goldenberg et al. (2012). Antithrombotic Therapy in Neonates and Children. CHEST Journal , 141 (2) , e737S-e801S. https://doi.org/10.1378/chest.11-2308

Identifiers

DOI
10.1378/chest.11-2308
PMID
22315277
PMCID
PMC3278066

Data Quality

Data completeness: 86%